Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary study objective is to demonstrate the efficacy of a single treatment of an injectable liquid form of Clostridium botulinum toxin type A haemagglutinin complex (BTX A HAC; hereafter referred to as BTX A HAC Next Generation (BTX A HAC NG)), used for the improvement in the appearance of moderate to severe glabellar lines at maximum frown. The primary objective will be accomplished by demonstrating the superiority of BTX A HAC NG over placebo assessed by the Investigator’s live assessment (ILA) of the appearance of glabellar lines at maximum frown at Day 29.
Critère d'inclusion
- moderate-to-severe glabellar lines